Fisherbroyles, LLP
Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Board of Regents of The University of Texas System
Y C C C G G G A
Y10T C12Q C12Q C12Q G01N G01N G01N A61P
additional inventional additional inventional inventional inventional inventional inventional
Dihua Francisco J. Xiaoyan Aysegul A. Yoichi
Yu Esteva Zhou Sahin Nagata